The view of the pharmaceutical industry.
Rhône-Poulenc Rorer has committed itself to the development of artemether because we believe the drug will be of considerable benefit to sufferers from severe falciparum malaria, and because it is a stable, effective and economical compound that can be given by intramuscular injection. The quality of the pharmaceutical product meets international regulatory standards. Artemether is unlikely to yield big profits, but we believe that major pharmaceutical companies have a responsibility to develop such much-needed products. To develop this project further, we will need the assistance of academic institutions, research organizations and international bodies.
Roche
G
G
Rhône-Poulenc Rorer, Antomy, France.
Helenport
J P
JP
D000962:Antimalarials; D000981:Antiprotozoal Agents; D000077549:Artemether; D037621:Artemisinins; D001290:Attitude; D004341:Drug Evaluation; D004345:Drug Industry; D006801:Humans; D012717:Sesquiterpenes; D013678:Technology, Pharmaceutical
D000962:Antimalarials; D000981:Antiprotozoal Agents; D037621:Artemisinins; D012717:Sesquiterpenes; D000077549:Artemether